{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:02Z","timestamp":1792787942851,"version":"4.5.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science and Technology Project of Luzhou Government","award":["2019-JYJ-51"],"award-info":[{"award-number":["2019-JYJ-51"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic cancer is one of the most lethal malignant tumors with a low survival rate, partly because the tumor microenvironment (TME), which consists of extracellular matrix (ECM), cancer-associated fibroblasts (CAFs), immune cells, and vascular systems, prevents effective drug delivery and chemoradiotherapy. Thus, modulating the microenvironment of pancreatic cancer is considered a promising therapeutic approach. Since nanoparticles are one of the most effective cancer treatment strategies, several nano-delivery platforms have been developed to regulate the TME and enhance treatment. Here, we summarize the latest advances in nano-delivery systems that alter the TME in pancreatic cancer by depleting ECM, inhibiting CAFs, reversing immunosuppression, promoting angiogenesis, or improving the hypoxic environment. We also discuss promising new targets for such systems. This review is expected to improve our understanding of how to modulate the pancreatic cancer microenvironment and guide the development of new therapies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12951-021-01134-6","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T06:02:53Z","timestamp":1637560973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy"],"prefix":"10.1186","volume":"19","author":[{"given":"Ming","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"issue":"44","key":"1134_CR1","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","volume":"22","author":"M Ilic","year":"2016","unstructured":"Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694\u2013705.","journal-title":"World J Gastroenterol"},{"issue":"16","key":"1134_CR2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2217\/fon-2016-0010","volume":"12","author":"D Ansari","year":"2016","unstructured":"Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12(16):1929\u201346.","journal-title":"Future Oncol"},{"issue":"14","key":"1134_CR3","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.7314\/APJCP.2015.16.14.5619","volume":"16","author":"V Goral","year":"2015","unstructured":"Goral V. Pancreatic cancer: pathogenesis and diagnosis. Asian Pac J Cancer Prev. 2015;16(14):5619\u201324.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"26","key":"1134_CR4","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.3748\/wjg.v21.i26.7988","volume":"21","author":"QJ Lin","year":"2015","unstructured":"Lin QJ, Yang F, Jin C, Fu DL. Current status and progress of pancreatic cancer in China. World J Gastroenterol. 2015;21(26):7988\u20138003.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1134_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2019.188318","volume":"1873","author":"J Carmicheal","year":"2020","unstructured":"Carmicheal J, Patel A, Dalal V, Atri P, Dhaliwal AS, Wittel UA, et al. Elevating pancreatic cystic lesion stratification: current and future pancreatic cancer biomarker(s). Biochim Biophys Acta Rev Cancer. 2020;1873(1): 188318.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"12","key":"1134_CR6","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrclinonc.2016.119","volume":"13","author":"PP Adiseshaiah","year":"2016","unstructured":"Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol. 2016;13(12):750\u201365.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1134_CR7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00018-019-03278-z","volume":"77","author":"J Yang","year":"2020","unstructured":"Yang J, Ren B, Yang G, Wang H, Chen G, You L, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol Life Sci. 2020;77(2):305\u201321.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"1134_CR8","first-page":"1937","volume":"10","author":"S Wang","year":"2020","unstructured":"Wang S, Li Y, Xing C, Ding C, Zhang H, Chen L, et al. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Am J Cancer Res. 2020;10(7):1937\u201353.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1134_CR9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","volume":"121","author":"E Karamitopoulou","year":"2019","unstructured":"Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Br J Cancer. 2019;121(1):5\u201314.","journal-title":"Br J Cancer"},{"issue":"4","key":"1134_CR10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/MPA.0000000000000499","volume":"45","author":"T Nishida","year":"2016","unstructured":"Nishida T, Yoshitomi H, Takano S, Kagawa S, Shimizu H, Ohtsuka M, et al. Low stromal area and high stromal microvessel density predict poor prognosis in pancreatic cancer. Pancreas. 2016;45(4):593\u2013600.","journal-title":"Pancreas"},{"issue":"6","key":"1134_CR11","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1021\/acs.nanolett.9b00374","volume":"19","author":"X Chen","year":"2019","unstructured":"Chen X, Zhou W, Liang C, Shi S, Yu X, Chen Q, et al. Codelivery nanosystem targeting the deep microenvironment of pancreatic cancer. Nano Lett. 2019;19(6):3527\u201334.","journal-title":"Nano Lett"},{"issue":"9","key":"1134_CR12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17(9):527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"1134_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119742","volume":"240","author":"J Kokkinos","year":"2020","unstructured":"Kokkinos J, Ignacio RMC, Sharbeen G, Boyer C, Gonzales-Aloy E, Goldstein D, et al. Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Biomaterials. 2020;240: 119742.","journal-title":"Biomaterials"},{"issue":"42","key":"1134_CR14","doi-asserted-by":"crossref","first-page":"68954","DOI":"10.18632\/oncotarget.12135","volume":"7","author":"J Wu","year":"2016","unstructured":"Wu J, Liang C, Chen M, Su W. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Oncotarget. 2016;7(42):68954\u201365.","journal-title":"Oncotarget"},{"issue":"1","key":"1134_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10456-018-9645-2","volume":"22","author":"S Li","year":"2019","unstructured":"Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, et al. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis. 2019;22(1):15\u201336.","journal-title":"Angiogenesis"},{"issue":"2","key":"1134_CR16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001250","volume":"8","author":"BC Selvanesan","year":"2020","unstructured":"Selvanesan BC, Meena K, Beck A, Meheus L, Lara O, Rooman I, et al. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice. J Immunother Cancer. 2020;8(2): e001250.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1134_CR17","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1245\/s10434-020-09367-9","volume":"28","author":"FG Rocha","year":"2021","unstructured":"Rocha FG. Landmark series: immunotherapy and targeted therapy for pancreatic cancer. Ann Surg Oncol. 2021;28(3):1400\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"26","key":"1134_CR18","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.2174\/0929867328666210319144347","volume":"28","author":"A Magri","year":"2021","unstructured":"Magri A, Baveloni FG, de Camargo BAF, Chorilli M. The emerging landscapes to drug delivery systems for the treatment of pancreatic cancer. Curr Med Chem. 2021;28(26):5411\u201330.","journal-title":"Curr Med Chem"},{"issue":"1054","key":"1134_CR19","doi-asserted-by":"crossref","first-page":"20150207","DOI":"10.1259\/bjr.20150207","volume":"88","author":"SC Baetke","year":"2015","unstructured":"Baetke SC, Lammers T, Kiessling F. Applications of NPs for diagnosis and therapy of cancer. Br J Radiol. 2015;88(1054):20150207.","journal-title":"Br J Radiol"},{"issue":"4","key":"1134_CR20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017017845","volume":"34","author":"UA Ashfaq","year":"2017","unstructured":"Ashfaq UA, Riaz M, Yasmeen E, Yousaf MZ. Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment. Crit Rev Ther Drug Carrier Syst. 2017;34(4):317\u201353.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"1134_CR21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.phrs.2017.05.004","volume":"126","author":"S Yang","year":"2017","unstructured":"Yang S, Gao H. NPs for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res. 2017;126:97\u2013108.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1134_CR22","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1152\/physrev.00042.2019","volume":"100","author":"E Hessmann","year":"2020","unstructured":"Hessmann E, Buchholz SM, Demir IE, Singh SK, Gress TM, Ellenrieder V, et al. Microenvironmental determinants of pancreatic cancer. Physiol Rev. 2020;100(4):1707\u201351.","journal-title":"Physiol Rev"},{"issue":"1","key":"1134_CR23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/gutjnl-2018-316451","volume":"68","author":"A Neesse","year":"2019","unstructured":"Neesse A, Bauer CA, \u00d6hlund D, Lauth M, Buchholz M, Michl P, et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut. 2019;68(1):159\u201371.","journal-title":"Gut"},{"issue":"8","key":"1134_CR24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487\u2013505.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1134_CR25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","volume":"21","author":"TR Cox","year":"2021","unstructured":"Cox TR. The matrix in cancer. Nat Rev Cancer. 2021;21(4):217\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1134_CR26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000360545","volume":"27","author":"J Wohlrab","year":"2014","unstructured":"Wohlrab J, Wohlrab D, Wohlrab L, Wohlrab C, Wohlrab A. Use of hyaluronidase for pharmacokinetic increase in bioavailability of intracutaneously applied substances. Skin Pharmacol Physiol. 2014;27(5):276\u201382.","journal-title":"Skin Pharmacol Physiol"},{"issue":"6","key":"1134_CR27","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1158\/1078-0432.CCR-15-1615","volume":"23","author":"Y Zhong","year":"2017","unstructured":"Zhong Y, Macgregor-Das A, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, et al. Mutant p53 together with TGF\u03b2 signaling influence organ-specific hematogenous colonization patterns of pancreatic cancer. Clin Cancer Res. 2017;23(6):1607\u201320.","journal-title":"Clin Cancer Res"},{"key":"1134_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100787","volume":"48","author":"I Sidhu","year":"2021","unstructured":"Sidhu I, Barwe SP, Gopalakrishnapillai A. The extracellular matrix: a key player in the pathogenesis of hematologic malignancies. Blood Rev. 2021;48: 100787.","journal-title":"Blood Rev"},{"issue":"1","key":"1134_CR29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41551-020-00657-x","volume":"5","author":"M Jang","year":"2021","unstructured":"Jang M, An J, Oh SW, Lim JY, Kim J, Choi JK, et al. Matrix stiffness epigenetically regulates the oncogenic activation of the Yes-associated protein in gastric cancer. Nat Biomed Eng. 2021;5(1):114\u201323.","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"1134_CR30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188356","volume":"1873","author":"B Piersma","year":"2020","unstructured":"Piersma B, Hayward MK, Weaver VM. Fibrosis and cancer: a strained relationship. Biochim Biophys Acta Rev Cancer. 2020;1873(2): 188356.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1134_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.14","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, Chan WCW. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016. https:\/\/doi.org\/10.1038\/natrevmats.2016.14.","journal-title":"Nat Rev Mater"},{"issue":"4 Suppl","key":"1134_CR32","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.amjsurg.2007.05.004","volume":"194","author":"M Korc","year":"2007","unstructured":"Korc M. Pancreatic cancer-associated stroma production. Am J Surg. 2007;194(4 Suppl):S84\u20136.","journal-title":"Am J Surg"},{"issue":"3","key":"1134_CR33","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s12015-020-10070-1","volume":"17","author":"K Girigoswami","year":"2021","unstructured":"Girigoswami K, Saini D, Girigoswami A. Extracellular matrix remodeling and development of cancer. Stem Cell Rev Rep. 2021;17(3):739\u201347.","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"1134_CR34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/fon-2017-0338","volume":"14","author":"GJ Doherty","year":"2018","unstructured":"Doherty GJ, Tempero M, Corrie PG. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018;14(1):13\u201322.","journal-title":"Future Oncol"},{"issue":"21","key":"1134_CR35","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.4161\/cc.7.21.7014","volume":"7","author":"S Sohr","year":"2008","unstructured":"Sohr S, Engeland K. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle. 2008;7(21):3448\u201360.","journal-title":"Cell Cycle"},{"issue":"15","key":"1134_CR36","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21(15):3561\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1134_CR37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112\u201320.","journal-title":"Gut"},{"issue":"5","key":"1134_CR38","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1021\/acs.nanolett.6b00820","volume":"16","author":"H Zhou","year":"2016","unstructured":"Zhou H, Fan Z, Deng J, Lemons PK, Arhontoulis DC, Bowne WB, et al. Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy. Nano Lett. 2016;16(5):3268\u201377.","journal-title":"Nano Lett"},{"issue":"324","key":"1134_CR39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jconrel.2020.06.001","volume":"10","author":"D Chen","year":"2020","unstructured":"Chen D, Zhu X, Tao W, Kong Y, Huag Y, Zhang Y, et al. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. J Control Release. 2020;10(324):545\u201359.","journal-title":"J Control Release"},{"key":"1134_CR40","doi-asserted-by":"crossref","first-page":"1902440","DOI":"10.1002\/adfm.201902440","volume":"29","author":"H Wang","year":"2019","unstructured":"Wang H, Han X, Dong Z, et al. Hyaluronidase with pH-responsive dextran modification as an adjuvant nanomedicine for enhanced photodynamic-immunotherapy of cancer. Adv Funct Mater. 2019;29:1902440.","journal-title":"Adv Funct Mater"},{"key":"1134_CR41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-981-13-7709-9_12","volume":"1148","author":"GC Weber","year":"2019","unstructured":"Weber GC, Buhren BA, Schrumpf H, Wohlrab J, Gerber PA. Clinical applications of hyaluronidase. Adv Exp Med Biol. 2019;1148:255\u201377.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1134_CR42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12967-019-2058-1","volume":"17","author":"S Xu","year":"2019","unstructured":"Xu S, Xu H, Wang W, Li S, Li H, Li T, et al. The role of collagen in cancer: from bench to bedside. J Transl Med. 2019;17(1):309.","journal-title":"J Transl Med"},{"issue":"5","key":"1134_CR43","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ceb.2010.08.015","volume":"22","author":"M Egeblad","year":"2010","unstructured":"Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):697\u2013706.","journal-title":"Curr Opin Cell Biol"},{"issue":"10","key":"1134_CR44","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1002\/ijc.32751","volume":"146","author":"IM Chen","year":"2020","unstructured":"Chen IM, Willumsen N, Dehlendorff C, Johansen AZ, Jensen BV, Hansen CP, et al. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Int J Cancer. 2020;146(10):2913\u201322.","journal-title":"Int J Cancer"},{"issue":"74","key":"1134_CR45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.actbio.2018.05.007","volume":"1","author":"MR Villegas","year":"2018","unstructured":"Villegas MR, Baeza A, Usategui A, Ortiz-Romero PL, Pablos JL, Vallet-Reg\u00ed M. Collagenase nanocapsules: an approach to fibrosis treatment. Acta Biomater. 2018;1(74):430\u20138.","journal-title":"Acta Biomater"},{"issue":"10","key":"1134_CR46","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1021\/acsnano.9b02395","volume":"13","author":"A Zinger","year":"2019","unstructured":"Zinger A, Koren L, Adir O, Poley M, Alyan M, Yaari Z, et al. Collagenase NPs enhance the penetration of drugs into pancreatic tumors. ACS Nano. 2019;13(10):11008\u201321.","journal-title":"ACS Nano"},{"issue":"6","key":"1134_CR47","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00018-017-2678-7","volume":"75","author":"C Liang","year":"2018","unstructured":"Liang C, Shi S, Meng Q, Liang D, Ji S, Zhang B, et al. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Cell Mol Life Sci. 2018;75(6):1001\u201312.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"1134_CR48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2217\/nnm-2016-0375","volume":"12","author":"Z Amoozgar","year":"2017","unstructured":"Amoozgar Z, Goldberg MS. Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules. Nanomedicine (Lond). 2017;12(7):729\u201343.","journal-title":"Nanomedicine (Lond)"},{"issue":"1","key":"1134_CR49","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/10717544.2018.1474971","volume":"25","author":"A Pan","year":"2018","unstructured":"Pan A, Wang Z, Chen B, Dai W, Zhang H, He B, et al. Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft. Drug Deliv. 2018;25(1):1495\u2013503.","journal-title":"Drug Deliv"},{"issue":"6","key":"1134_CR50","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1021\/acs.molpharmaceut.8b00319","volume":"15","author":"A Dolor","year":"2018","unstructured":"Dolor A, Szoka FC Jr. Digesting a path forward: the utility of collagenase tumor treatment for improved drug delivery. Mol Pharm. 2018;15(6):2069\u201383.","journal-title":"Mol Pharm"},{"key":"1134_CR51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/bs.pmbts.2017.03.004","volume":"148","author":"AM Knapinska","year":"2017","unstructured":"Knapinska AM, Estrada CA, Fields GB. The roles of matrix metalloproteinases in pancreatic cancer. Prog Mol Biol Transl Sci. 2017;148:339\u201354.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"14","key":"1134_CR52","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.2147\/DDDT.S270303","volume":"23","author":"N Yin","year":"2020","unstructured":"Yin N, Yu H, Zhang X, Lv X. Enhancement of pancreatic cancer therapy efficacy by type-1 matrix metalloproteinase-functionalized NPs for the selective delivery of gemcitabine and erlotinib. Drug Des Devel Ther. 2020;23(14):4465\u201375.","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"1134_CR53","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/mp500108p","volume":"11","author":"PS Kulkarni","year":"2014","unstructured":"Kulkarni PS, Haldar MK, Nahire RR, Katti P, Ambre AH, Muhonen WW, et al. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Mol Pharm. 2014;11(7):2390\u20139.","journal-title":"Mol Pharm"},{"issue":"1","key":"1134_CR54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jso.24643","volume":"116","author":"LG Melstrom","year":"2017","unstructured":"Melstrom LG, Salazar MD, Diamond DJ. The pancreatic cancer microenvironment: a true double agent. J Surg Oncol. 2017;116(1):7\u201315.","journal-title":"J Surg Oncol"},{"issue":"1","key":"1134_CR55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13045-017-0448-5","volume":"10","author":"D von Ahrens","year":"2017","unstructured":"von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol. 2017;10(1):76.","journal-title":"J Hematol Oncol"},{"issue":"321","key":"1134_CR56","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jconrel.2020.02.040","volume":"10","author":"Q Yu","year":"2020","unstructured":"Yu Q, Qiu Y, Li J, Tang X, Wang X, Cun X, et al. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin NPs to enhance drug perfusion for pancreatic tumor therapy. J Control Release. 2020;10(321):564\u201375.","journal-title":"J Control Release"},{"issue":"1","key":"1134_CR57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147\u201376.","journal-title":"Physiol Rev"},{"issue":"2","key":"1134_CR58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10911-020-09475-y","volume":"26","author":"MB Giorello","year":"2021","unstructured":"Giorello MB, Borzone FR, Labovsky V, Piccioni FV, Chasseing NA. Cancer-associated fibroblasts in the breast tumor microenvironment. J Mammary Gland Biol Neoplasia. 2021;26(2):135\u201355.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"3","key":"1134_CR59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/apm.12482","volume":"124","author":"E Lakiotaki","year":"2016","unstructured":"Lakiotaki E, Sakellariou S, Evangelou K, Liapis G, Patsouris E, Delladetsima I. Vascular and ductal elastotic changes in pancreatic cancer. APMIS. 2016;124(3):181\u20137.","journal-title":"APMIS"},{"issue":"11","key":"1134_CR60","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.trecan.2019.09.010","volume":"5","author":"BA Pereira","year":"2019","unstructured":"Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, et al. CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer. Trends Cancer. 2019;5(11):724\u201341.","journal-title":"Trends Cancer"},{"key":"1134_CR61","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.621070","volume":"8","author":"J Linares","year":"2021","unstructured":"Linares J, Mar\u00edn-Jim\u00e9nez JA, Badia-Ramentol J, Calon A. Determinants and functions of CAFs secretome during cancer progression and therapy. Front Cell Dev Biol. 2021;8: 621070.","journal-title":"Front Cell Dev Biol."},{"key":"1134_CR62","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119907","volume":"241","author":"J Feng","year":"2020","unstructured":"Feng J, Xu M, Wang J, Zhou S, Liu Y, Liu S, et al. Sequential delivery of nanoformulated \u03b1-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer. Biomaterials. 2020;241: 119907.","journal-title":"Biomaterials"},{"issue":"sup1","key":"1134_CR63","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/21691401.2018.1445093","volume":"46","author":"T Jiang","year":"2018","unstructured":"Jiang T, Zhang B, Zhang L, Wu X, Li H, Shen S, et al. Biomimetic NPs delivered hedgehog pathway inhibitor to modify tumour microenvironment and improved chemotherapy for pancreatic carcinoma. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1088\u2013101.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1134_CR64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biomaterials.2018.01.014","volume":"159","author":"J Zhao","year":"2018","unstructured":"Zhao J, Wang H, Hsiao CH, Chow DS, Koay EJ, Kang Y, et al. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 2018;159:215\u201328.","journal-title":"Biomaterials"},{"issue":"29","key":"1134_CR65","doi-asserted-by":"crossref","first-page":"26060","DOI":"10.1021\/acsami.9b03313","volume":"11","author":"MN Hossen","year":"2019","unstructured":"Hossen MN, Rao G, Dey A, Robertson JD, Bhattacharya R, Mukherjee P. Gold nanoparticle transforms activated cancer-associated fibroblasts to quiescence. ACS Appl Mater Interfaces. 2019;11(29):26060\u20138.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1134_CR66","volume":"183","author":"N Cheng","year":"2021","unstructured":"Cheng N, Bai X, Shu Y, Ahmad O, Shen P. Targeting tumor-associated macrophages as an antitumor strategy. Biochem Pharmacol. 2021;183: 114354.","journal-title":"Biochem Pharmacol"},{"key":"1134_CR67","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111442","volume":"197","author":"H Peng","year":"2021","unstructured":"Peng H, Wang JH, Guo F, Zhu FF, Wen ZJ, Zhong HJ, et al. Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and cancer chemotherapy. Colloids Surf B Biointerfaces. 2021;197: 111442.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"3","key":"1134_CR68","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1158\/2326-6066.CIR-16-0125","volume":"5","author":"J Cullis","year":"2017","unstructured":"Cullis J, Siolas D, Avanzi A, Barui S, Maitra A, Bar-Sagi D. Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol Res. 2017;5(3):182\u201390.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1134_CR69","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.13","volume":"11","author":"N Wang","year":"2021","unstructured":"Wang N, Wang S, Wang X, Zheng Y, Yang B, Zhang J, et al. Research trends in pharmacological modulation of tumor-associated macrophages. Clin Transl Med. 2021;11(1): e288.","journal-title":"Clin Transl Med"},{"issue":"2","key":"1134_CR70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.canlet.2012.09.001","volume":"334","author":"K Yokoi","year":"2013","unstructured":"Yokoi K, Godin B, Oborn CJ, Alexander JF, Liu X, Fidler IJ, et al. Porous silicon nanocarriers for dual targeting tumor associated endothelial cells and macrophages in stroma of orthotopic human pancreatic cancers. Cancer Lett. 2013;334(2):319\u201327.","journal-title":"Cancer Lett"},{"issue":"321","key":"1134_CR71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2020.02.011","volume":"10","author":"M Li","year":"2020","unstructured":"Li M, Li M, Yang Y, Liu Y, Xie H, Yu Q, et al. Remodeling tumor immune microenvironment via targeted blockade of PI3K-\u03b3 and CSF-1\/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy. J Control Release. 2020;10(321):23\u201335.","journal-title":"J Control Release"},{"issue":"3","key":"1134_CR72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ymthe.2018.11.012","volume":"27","author":"M Das","year":"2019","unstructured":"Das M, Shen L, Liu Q, Goodwin TJ, Huang L. Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer. Mol Ther. 2019;27(3):507\u201317.","journal-title":"Mol Ther"},{"issue":"8","key":"1134_CR73","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1021\/acs.nanolett.9b01807","volume":"19","author":"H Huang","year":"2019","unstructured":"Huang H, Jiang CT, Shen S, Liu A, Gan YJ, Tong QS, et al. Nanoenabled reversal of IDO1-mediated immunosuppression synergizes with immunogenic chemotherapy for improved cancer therapy. Nano Lett. 2019;19(8):5356\u201365.","journal-title":"Nano Lett"},{"issue":"1","key":"1134_CR74","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","volume":"8","author":"J Lu","year":"2017","unstructured":"Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017;8(1):1811.","journal-title":"Nat Commun"},{"issue":"4","key":"1134_CR75","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm.1941","volume":"15","author":"AR Reynolds","year":"2009","unstructured":"Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15(4):392\u2013400.","journal-title":"Nat Med"},{"issue":"7","key":"1134_CR76","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/0092-8674(94)90007-8","volume":"79","author":"PC Brooks","year":"1994","unstructured":"Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79(7):1157\u201364.","journal-title":"Cell"},{"issue":"3","key":"1134_CR77","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/fon.11.8","volume":"7","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide \u03b1\u03bd\u03b23 and \u03b1\u03bd\u03b25 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011;7(3):339\u201354.","journal-title":"Future Oncol"},{"issue":"10","key":"1134_CR78","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","volume":"10","author":"C Mas-Moruno","year":"2010","unstructured":"Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10(10):753\u201368.","journal-title":"Anticancer Agents Med Chem"},{"issue":"17","key":"1134_CR79","doi-asserted-by":"crossref","first-page":"1902746","DOI":"10.1002\/advs.201902746","volume":"7","author":"Y Wei","year":"2020","unstructured":"Wei Y, Song S, Duan N, Wang F, Wang Y, Yang Y, et al. MT1-MMP-activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy. Adv Sci (Weinh). 2020;7(17):1902746.","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"1134_CR80","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719\u201334.","journal-title":"Cancer Cell"},{"issue":"6","key":"1134_CR81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735\u201347.","journal-title":"Cancer Cell"},{"issue":"3","key":"1134_CR82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/17474124.2016.1117386","volume":"10","author":"M Erkan","year":"2016","unstructured":"Erkan M, Kurtoglu M, Kleeff J. The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev Gastroenterol Hepatol. 2016;10(3):301\u201316.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1134_CR83","volume":"141","author":"X Hao","year":"2021","unstructured":"Hao X, Ren Y, Feng M, Wang Q, Wang Y. Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more. Biomed Pharmacother. 2021;141: 111798.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1134_CR84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-020-01030-w","volume":"14","author":"J Tao","year":"2021","unstructured":"Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021;14(1):14.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1134_CR85","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108105","volume":"32","author":"C Donato","year":"2020","unstructured":"Donato C, Kunz L, Castro-Giner F, Paasinen-Sohns A, Strittmatter K, Szczerba BM, et al. Hypoxia triggers the intravasation of clustered circulating tumor cells. Cell Rep. 2020;32(10): 108105.","journal-title":"Cell Rep"},{"issue":"16","key":"1134_CR86","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","volume":"18","author":"C Feig","year":"2012","unstructured":"Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18(16):4266\u201376.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1134_CR87","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/MPA.0000000000001828","volume":"50","author":"R Mu","year":"2021","unstructured":"Mu R, Zou YK, Tu K, Wang DB, Tang D, Yu Z, et al. Hypoxia promotes pancreatic cancer cell dedifferentiation to stem-like cell phenotypes with high tumorigenic potential by the HIF-1\u03b1\/notch signaling pathway. Pancreas. 2021;50(5):756\u201365.","journal-title":"Pancreas"},{"issue":"2","key":"1134_CR88","first-page":"2176","volume":"13","author":"J Lang","year":"2019","unstructured":"Lang J, Zhao X, Wang X, Zhao Y, Li Y, Zhao R, et al. Targeted co-delivery of the iron chelator deferoxamine and a HIF1\u03b1 inhibitor impairs pancreatic tumor growth. ACS Nano. 2019;13(2):2176\u201389.","journal-title":"ACS Nano"},{"issue":"2","key":"1134_CR89","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/sj.cgt.7700871","volume":"13","author":"T Mizuno","year":"2006","unstructured":"Mizuno T, Nagao M, Yamada Y, Narikiyo M, Ueno M, Miyagishi M, et al. Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther. 2006;13(2):131\u201340.","journal-title":"Cancer Gene Ther"},{"key":"1134_CR90","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2014.12.028","volume":"46","author":"X Zhao","year":"2015","unstructured":"Zhao X, Li F, Li Y, Wang H, Ren H, Chen J, et al. Co-delivery of HIF1\u03b1 siRNA and gemcitabine via biocompatible lipid-polymer hybrid NPs for effective treatment of pancreatic cancer. Biomaterials. 2015;46:13\u201325.","journal-title":"Biomaterials"},{"issue":"2","key":"1134_CR91","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"M Danaei","year":"2018","unstructured":"Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10(2):57.","journal-title":"Pharmaceutics"},{"issue":"7","key":"1134_CR92","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/1061186X.2018.1552276","volume":"27","author":"C Lin","year":"2019","unstructured":"Lin C, Hu Z, Yuan G, Su H, Zeng Y, Guo Z, et al. HIF1\u03b1-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers. J Drug Target. 2019;27(7):797\u2013805.","journal-title":"J Drug Target"},{"issue":"203","key":"1134_CR93","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2015.02.004","volume":"10","author":"C McEwan","year":"2015","unstructured":"McEwan C, Owen J, Stride E, Fowley C, Nesbitt H, Cochrane D, et al. Oxygen carrying microbubbles for enhanced sonodynamic therapy of hypoxic tumours. J Control Release. 2015;10(203):51\u20136.","journal-title":"J Control Release"},{"issue":"262","key":"1134_CR94","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2017.07.040","volume":"28","author":"Y Sheng","year":"2017","unstructured":"Sheng Y, Beguin E, Nesbitt H, Kamila S, Owen J, Barnsley LC, et al. Magnetically responsive microbubbles as delivery vehicles for targeted sonodynamic and antimetabolite therapy of pancreatic cancer. J Control Release. 2017;28(262):192\u2013200.","journal-title":"J Control Release"},{"key":"1134_CR95","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.biomaterials.2015.11.033","volume":"80","author":"C McEwan","year":"2016","unstructured":"McEwan C, Kamila S, Owen J, Nesbitt H, Callan B, Borden M, et al. Combined sonodynamic and antimetabolite therapy for the improved treatment of pancreatic cancer using oxygen loaded microbubbles as a delivery vehicle. Biomaterials. 2016;80:20\u201332.","journal-title":"Biomaterials"},{"issue":"12","key":"1134_CR96","doi-asserted-by":"crossref","first-page":"12849","DOI":"10.1021\/acsnano.7b08225","volume":"11","author":"J Chen","year":"2017","unstructured":"Chen J, Luo H, Liu Y, Zhang W, Li H, Luo T, et al. Oxygen-self-produced nanoplatform for relieving hypoxia and breaking resistance to sonodynamic treatment of pancreatic cancer. ACS Nano. 2017;11(12):12849\u201362.","journal-title":"ACS Nano"},{"issue":"264","key":"1134_CR97","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2017.09.004","volume":"28","author":"Y Sheng","year":"2017","unstructured":"Sheng Y, Nesbitt H, Callan B, Taylor MA, Love M, McHale AP, et al. Oxygen generating NPs for improved photodynamic therapy of hypoxic tumours. J Control Release. 2017;28(264):333\u201340.","journal-title":"J Control Release"},{"issue":"1","key":"1134_CR98","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1021\/acsnano.5b06779","volume":"10","author":"M Song","year":"2016","unstructured":"Song M, Liu T, Shi C, Zhang X, Chen X. Bioconjugated manganese dioxide NPs enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano. 2016;10(1):633\u201347.","journal-title":"ACS Nano"},{"issue":"1","key":"1134_CR99","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41467-017-01050-0","volume":"8","author":"G Yang","year":"2017","unstructured":"Yang G, Xu L, Chao Y, Xu J, Sun X, Wu Y, et al. Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun. 2017;8(1):902.","journal-title":"Nat Commun"},{"issue":"1","key":"1134_CR100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","volume":"172","author":"AS Abu Lila","year":"2013","unstructured":"Abu Lila AS, Kiwada H, Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release. 2013;172(1):38\u201347.","journal-title":"J Control Release"},{"issue":"12","key":"1134_CR101","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/md16120510","volume":"16","author":"SW Shin","year":"2018","unstructured":"Shin SW, Jung W, Choi C, Kim SY, Son A, Kim H, et al. Fucoidan-manganese dioxide NPs potentiate radiation therapy by co-targeting tumor hypoxia and angiogenesis. Mar Drugs. 2018;16(12):510.","journal-title":"Mar Drugs"},{"issue":"35","key":"1134_CR102","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1039\/C9CC01386E","volume":"55","author":"W Pan","year":"2019","unstructured":"Pan W, Ge Y, Yu Z, Zhou P, Cui B, Li N, et al. A cancer cell membrane-encapsulated MnO2 nanoreactor for combined photodynamic-starvation therapy. Chem Commun (Camb). 2019;55(35):5115\u20138.","journal-title":"Chem Commun (Camb)"},{"issue":"7","key":"1134_CR103","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1021\/acsnano.7b02533","volume":"11","author":"SY Li","year":"2017","unstructured":"Li SY, Cheng H, Xie BR, Qiu WX, Zeng JY, Li CX, et al. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy. ACS Nano. 2017;11(7):7006\u201318.","journal-title":"ACS Nano"},{"issue":"37","key":"1134_CR104","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.2174\/0929867322666151021111016","volume":"22","author":"D Liang","year":"2015","unstructured":"Liang D, Miller GH, Tranmer GK. Hypoxia activated prodrugs: factors influencing design and development. Curr Med Chem. 2015;22(37):4313\u201325.","journal-title":"Curr Med Chem"},{"issue":"1","key":"1134_CR105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drudis.2018.09.019","volume":"24","author":"M Gulfam","year":"2019","unstructured":"Gulfam M, Sahle FF, Lowe TL. Design strategies for chemical-stimuli-responsive programmable nanotherapeutics. Drug Discov Today. 2019;24(1):129\u201347.","journal-title":"Drug Discov Today"},{"issue":"8","key":"1134_CR106","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1021\/acs.biomac.6b00350","volume":"17","author":"P Kulkarni","year":"2016","unstructured":"Kulkarni P, Haldar MK, You S, Choi Y, Mallik S. Hypoxia-responsive polymersomes for drug delivery to hypoxic pancreatic cancer cells. Biomacromol. 2016;17(8):2507\u201313.","journal-title":"Biomacromol"},{"issue":"13","key":"1134_CR107","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.2147\/IJN.S140462","volume":"4","author":"K Graham","year":"2018","unstructured":"Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomed. 2018;4(13):6049\u201358.","journal-title":"Int J Nanomed"},{"issue":"8","key":"1134_CR108","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1021\/acs.bioconjchem.6b00241","volume":"27","author":"P Kulkarni","year":"2016","unstructured":"Kulkarni P, Haldar MK, Katti P, Dawes C, You S, Choi Y, et al. Hypoxia responsive, tumor penetrating lipid NPs for delivery of chemotherapeutics to pancreatic cancer cell spheroids. Bioconjug Chem. 2016;27(8):1830\u20138.","journal-title":"Bioconjug Chem"},{"issue":"8","key":"1134_CR109","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.molpharmaceut.0c00247","volume":"17","author":"MI Confeld","year":"2020","unstructured":"Confeld MI, Mamnoon B, Feng L, Jensen-Smith H, Ray P, Froberg J, et al. Targeting the tumor core: hypoxia-responsive NPs for the delivery of chemotherapy to pancreatic tumors. Mol Pharm. 2020;17(8):2849\u201363.","journal-title":"Mol Pharm"},{"issue":"3","key":"1134_CR110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbrc.2019.02.116","volume":"511","author":"H Ichihara","year":"2019","unstructured":"Ichihara H, Motomura M, Matsumoto Y. Therapeutic effects and anti-metastasis effects of cationic liposomes against pancreatic cancer metastasis in vitro and in vivo. Biochem Biophys Res Commun. 2019;511(3):504\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"1134_CR111","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1166\/jbn.2018.2546","volume":"14","author":"G Lin","year":"2018","unstructured":"Lin G, Chen S, Mi P. Nanoparticles targeting and remodeling tumor microenvironment for cancer theranostics. J Biomed Nanotechnol. 2018;14(7):1189\u2013207.","journal-title":"J Biomed Nanotechnol"},{"issue":"3","key":"1134_CR112","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1134_CR113","doi-asserted-by":"crossref","first-page":"11740","DOI":"10.1021\/acsnano.8b05893","volume":"12","author":"S Musetti","year":"2018","unstructured":"Musetti S, Huang L. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy. ACS Nano. 2018;12(12):11740\u201355.","journal-title":"ACS Nano"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-01134-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-021-01134-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-01134-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T18:29:02Z","timestamp":1699813742000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-021-01134-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1186\/s12951-021-01134-6","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We give our consent for the manuscript to be published in Journal of Nanobiotechnology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}